Philip Scheltens (Edmond Sadaka/Sipa via AP Images)

As ven­ture fund­ing in on­col­o­gy flour­ish­es, neu­ro has seen shal­low­er pock­ets. A Eu­ro­pean in­vestor wants to change that

Big Phar­ma has re­treat­ed from neu­ro­science over the past sev­er­al years, aban­don­ing or trim­ming back pro­grams af­ter fac­ing set­backs in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA